MediWound Ltd. (MDWD) — Analysis Summary
MediWound Ltd. (MDWD) has a market cap of $170.93M with year-over-year revenue growth of -16.1%. Net margin stands at -140.8%. The stock trades at a P/E ratio of -7.2.
Key Takeaways
- Revenue changed -16.1% year-over-year
- Net margin of -140.8%
- P/E ratio of -7.2
Compared with its sector, MDWD posted revenue growth of -16.1% and trades at a P/E of -7.2.
MediWound Ltd. (MDWD)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -10.3x — earnings do not cover interest payments
Operating margin at -149.0% — severe operating losses
Net margin at -140.8% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Employees
121
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.